glucose, (beta-d)-isomer has been researched along with Diabetes Mellitus, Type 1 in 114 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.88) | 18.2507 |
| 2000's | 7 (6.14) | 29.6817 |
| 2010's | 64 (56.14) | 24.3611 |
| 2020's | 42 (36.84) | 2.80 |
| Authors | Studies |
|---|---|
| Gudi, R; Johnson, BM; Karumuthil-Melethil, S; Perez, N; Sofi, MH; Vasu, C | 1 |
| Karumuthil-Melethil, S; Li, R; Perez, N; Vasu, C | 1 |
| Huszarik, K; Krougly, O; Lee-Chan, E; Nikoopour, E; Sandrock, C; Schwartz, JA; Singh, B | 1 |
| Azuma, M; Burton, OT; Cooke, A; De La Peña, H; Fehérvári, Z; Gibbs, S; Phillips, JM; Stockinger, B; Zaccone, P | 1 |
| Gleiznys, A; Ivanauskienė, E; Saferis, V; Sakalauskienė, J; Surna, A | 1 |
| Bretzel, RG; Federlin, K; Hering, BJ; Jahr, H; Weinand, S | 1 |
| Abdalla, O; Dessouki, A; Kilany, O; Murata, I; Sasaki, K; Sayed, N | 1 |
| Bjornstad, P; Cherney, DZI; Marquard, J; Neubacher, D; Perkins, BA; Rosenstock, J; Soleymanlou, N | 1 |
| Arima, H; Banno, R; Hagiwara, D; Ito, Y; Iwama, S; Kobayashi, T; Mizoguchi, A; Onoue, T; Suga, H; Sugiyama, M; Sun, R; Takagi, H; Taki, K; Tsunekawa, T; Yaginuma, H | 1 |
| Han, Y; He, SM; Wang, DD; Wang, TY; Wang, YM | 1 |
| Boeder, SC; Giovannetti, ER; Gregory, JM; Pettus, JH | 1 |
| Bansiya, V; Boughton, CK; Evans, ML; Raj, A | 1 |
| Balogh, DB; Barczi, A; Fekete, A; Fintha, A; Hodrea, J; Molnar, A; Saeed, A; Szabo, AJ; Wagner, LJ | 1 |
| Herat, L; Matthews, J; Matthews, VB; Rakoczy, E; Rooney, J; Schlaich, M | 1 |
| Boulton, DW; Hamrén, B; Melin, J; Parkinson, J; Penland, RC; Rekić, D; Tang, W | 1 |
| Cardinez, N; Eldelekli, D; Falappa, CM; Ghanbari, M; Gouchie-Provencher, N; Haidar, A; Jafar, A; Lovblom, LE; Orszag, A; Perkins, BA; Rutkowski, J; Tsoukas, MA; Yale, JF | 1 |
| Cankar, M; France Štiglic, A; Janež, A; Janić, M; Jerin, A; Lunder, M; Šabovič, M; Šmid, J | 1 |
| Aktas, G; Bilgin, S; Duman, TT; Kurtkulagi, O; Yilmaz, F | 1 |
| Dong, L; Li, H; Li, Y; Lin, D; Lou, P; Ma, L; Wang, K; Xu, L; Zang, D | 1 |
| Adler, AI; Dent, R; Latimer, N; Ting, S | 1 |
| Jiang, YP; Liu, N; Ma, L; Niu, JG; Sun, T; Yang, JM; Ye, RJ; Yu, JQ; Zhang, WJ; Zheng, P | 1 |
| Araki, E; Asano, M; Fujii, H; Kim, H; Langkilde, AM; Ohashi, H; Okabe, T; Thoren, F; Tomonaga, O; Uchigata, Y; Watada, H; Yajima, T | 1 |
| Isaka, H; Kaku, K; Sakatani, T; Toyoshima, J | 3 |
| Elmokadem, A; Eudy-Byrne, RJ; George, JT; Johnston, CK; Laffel, LM; Liesenfeld, KH; Marquard, J; Neubacher, D; Nock, V; Perkins, BA; Riggs, MM; Rosenstock, J; Skyler, JS; Soleymanlou, N | 1 |
| Bennett, H; Bergenheim, K; Evans, M; McEwan, P; Tank, A | 1 |
| Erskine, D | 1 |
| Balogh, DB; Besztercei, B; Fekete, A; Genovese, F; Hodrea, J; Hosszu, A; Koszegi, S; Lenart, L; Sparding, N; Szabo, AJ; Wagner, LJ | 1 |
| Abdalla, O; Dessouki, A; Kilany, O; Sasaki, K; Sayed, N; Shimoda, M; Yoshida, T | 1 |
| Araki, E; Arya, N; Dandona, P; Iqbal, N; Lind, M; Mathieu, C; Phillip, M; Rudofsky, G; Scheerer, MF; Thorén, F | 1 |
| Birkenfeld, AL; Dandona, P; Hansen, TK; Iqbal, N; Mathieu, C; Phillip, M; Repetto, E; Scheerer, MF; Thoren, F; Xu, J | 1 |
| Chen, R; Li, N; Liu, K | 1 |
| Isaka, H; Kaibara, A; Saito, M; Sakatani, T; Toyoshima, J | 1 |
| Petrie, JR | 1 |
| Araki, E; Arya, N; Bergenstal, R; Dandona, P; di Bartolo, P; Hansen, L; Heller, S; Iqbal, N; Lind, M; Mathieu, C; Phillip, M; Scheerer, MF; Thoren, F; Xu, J | 1 |
| Dashora, U; Dhatariya, K; Gregory, R; Macklin, A; Nagi, D; Patel, DC; Rayman, G; Rowles, S; Winocour, P | 1 |
| Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Atlas, E; Battelino, T; Biester, T; Bratina, N; Danne, T; Dovc, K; Kordonouri, O; Muller, I; Nimri, R; Phillip, M; Scheerer, MF; von dem Berge, T | 1 |
| Habu, M; Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Abu-Zaid, A; Alhabeeb, H; Alomar, S; Altowairqi, AK; Baradhwan, A; Bhagavathul, AS; Dissanayaka, T; Oganesyan, A; Tom, S | 1 |
| Cardinez, N; El Fathi, A; Eldelekli, D; Falappa, CM; Gouchie-Provencher, N; Haidar, A; Lanctôt, SO; Lovblom, LE; Orszag, A; Perkins, BA; Rene, J; Scarr, D; Tsoukas, MA; Yale, JF | 1 |
| Bolli, GB; Fanelli, CG; Lucidi, P; Porcellati, F | 1 |
| Davies, M; Fielding, BA; Garesse, R; Herring, RA; Jackson, N; Johnsen, S; Mendis, A; Russell-Jones, DL; Shojaee-Moradie, F; Stevenage, M; Umpleby, AM | 1 |
| Araki, E; Arya, N; Asano, M; Ikeda, H; Iqbal, N; Maeda, H; Mathieu, C; Shiraiwa, T; Thoren, F | 1 |
| Haberbosch, L; Spranger, J | 1 |
| Ali, MT; Cherney, DZI; Kim, J; Lawler, PR; Liu, H; Lovblom, LE; Lytvyn, Y; Montemayor, D; Perkins, BA; Scarr, D; Sharma, K; Sridhar, VS; Ye, H | 1 |
| Fushimi, Y; Kaku, K; Kaneto, H; Katakura, Y; Kimura, T; Kohara, K; Mashiko, A; Mune, T; Nakanishi, S; Obata, A; Sanada, J; Shimoda, M; Tatsumi, F | 1 |
| de Galan, BE; Tack, CJ; van Meijel, LA | 1 |
| Fan, H; Liu, J; Ma, J; Zhao, Y | 1 |
| Aschemeier, B; Biester, T; Danne, T; Fath, M; Frey, M; Kordonouri, O; Scheerer, MF | 1 |
| Maltezos, E; Pafili, K; Papanas, N | 1 |
| Hosoyamada, M; Ishizawa, K; Kuribayashi-Okuma, E; Shibata, S; Toyoki, D; Uchida, S; Xu, N | 1 |
| Pereyra A, M; Ramírez, C; Román, R | 1 |
| Chen, XF; Li, XL; Song, Y; Yang, M; Zhang, Y | 1 |
| Al-Sharea, A; Goldberg, IJ; Hu, Y; Huggins, LA; Murphy, AJ; Nagareddy, PR | 1 |
| Caerels, S; Mathieu, C; Van den Mooter, L | 1 |
| Li, X; Wang, K; Wang, Y; Wu, Y | 1 |
| George, J; Hanafusa, T; Lee, G; Marquard, J; Sarashina, A; Shiki, K; Shimada, A; Soleymanlou, N; Taneda, Y; Yasui, A | 1 |
| Akturk, HK; Garg, SK; Rewers, A | 1 |
| Ebenbichler, CF; Kempf, P; Laimer, M; Lunger, L; Mader, JK; Melmer, A; Pieber, TR; Stettler, C; Tilg, H | 1 |
| Athyros, V; Doumas, M; Imprialos, K; Patoulias, D; Stavropoulos, K | 1 |
| Henry, RR; McCrimmon, RJ | 1 |
| Dandona, P; Hansen, L; Langkilde, AM; Mathieu, C; Phillip, M; Thorén, F; Tschöpe, D; Xu, J | 1 |
| Boulton, DW; Parkinson, J; Penland, RC; Sokolov, V; Tang, W; Ueda, S; Yakovleva, T | 1 |
| Cefalu, WT; Riddle, MC | 1 |
| Araki, E; Asano, M; Boulton, DW; Kim, H; Shiramoto, M; Tang, W; Thorén, F; Ueda, S; Watada, H; Yajima, T | 1 |
| Janež, A; Janić, M; Japelj, M; Juretič, A; Lunder, M; Šabovič, M | 1 |
| Åstrand, M; Boulton, DW; Ekholm, E; Hamrén, B; Melin, J; Parkinson, J; Tang, W | 1 |
| Garg, SK; Giordano, D | 1 |
| Dandona, P; Hansen, L; Langkilde, AM; Lind, M; Mathieu, C; Oron, T; Phillip, M; Thorén, F; Xu, J | 1 |
| Antlanger, M; Cherney, DZI; Domenig, O; Kaltenecker, CC; Kopecky, C; Kovarik, JJ; Lytvyn, Y; Perkins, BA; Poglitsch, M; Rye, KA; Säemann, MD | 1 |
| Biester, T; Boulton, D; Busse, D; Danne, T; Parkinson, J; Scheerer, M; Sokolov, V; Tang, W | 1 |
| Boeder, S; Edelman, SV | 1 |
| Gilbert, JD; Goldenberg, RM; Hramiak, IM; Woo, VC; Zinman, B | 1 |
| Gebel, E | 1 |
| Stanton, RC | 1 |
| Broedl, UC; Cherney, DZ; Fagan, NM; Johansen, OE; Lai, V; Lee, A; Maione, M; Perkins, BA; Soleymanlou, N; von Eynatten, M; Woerle, HJ | 1 |
| Broedl, UC; Cherney, DZ; Fagan, N; Har, R; Johansen, OE; Perkins, BA; Soleymanlou, N; von Eynatten, M; Woerle, HJ | 1 |
| Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Li, Q; Noda, A; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 1 |
| Broedl, UC; Cherney, DZ; Fagan, NM; Johansen, OE; Kaspers, S; Partridge, H; Perkins, BA; Soleymanlou, N; Tschirhart, H; Woerle, HJ; Zinman, B | 1 |
| Davis, SN; Lamos, EM; Younk, LM | 1 |
| Bogle, A; Chalamandaris, AG; Edelman, S; Griffen, SC; Henry, RR; Iqbal, N; Kasichayanula, S; List, J; Mudaliar, S; Rosenstock, J | 1 |
| Broedl, UC; Cherney, DZ; Hach, T; Johansen, OE; Lytvyn, Y; Perkins, BA; Silverman, M; Skrtić, M; Soleymanlou, N; von Eynatten, M; Woerle, HJ; Yang, GK | 1 |
| Vallon, V | 1 |
| Cherney, DZ; Lytvyn, Y; Perkins, BA; Škrtić, M; Yang, GK; Yip, PM | 1 |
| Cherney, DZ; Škrtić, M | 1 |
| Banks, P; Bode, BW; Buse, JB; Cefalu, WT; Garg, SK; Heptulla, R; Lapuerta, P; Rendell, M; Rosenstock, J; Sands, AT; Strumph, P; Zambrowicz, BP | 1 |
| Buschur, EO; Buse, JB; Cohan, P; Diner, JC; Hirsch, IB; Peters, AL | 1 |
| Broedl, UC; Cescutti, J; Eilbracht, J; Famulla, S; Johansen, OE; Kaspers, S; Pieber, TR; Soleymanlou, N; Woerle, HJ | 1 |
| Mikhail, N | 1 |
| Fioretto, P; Giaccari, A; Sesti, G | 1 |
| Boulton, DW; Johnsson, E; LaCreta, F; Leil, TA; Tang, W | 1 |
| Broedl, UC; Cherney, DZ; Fagan, N; Johansen, OE; Kaspers, S; Lee, JA; Mazze, R; Partridge, H; Perkins, BA; Soleymanlou, N; Tschirhart, H; Woerle, HJ; Zinman, B | 1 |
| Adkins, SE; Bokaie, BB; Shubrook, JH | 1 |
| Hirano, T; Hiromura, M; Kohashi, K; Kushima, H; Mori, Y; Nagashima, M; Terasaki, M; Watanabe, T | 1 |
| Close, KL; Gao, HX; Regier, EE | 1 |
| Bloomgarden, ZT | 1 |
| Chen, L; Cheng, ST; Leung, PS; Li, SY; Mayoux, E | 1 |
| Busetto, L; Fioretto, P; Rossato, M; Vettor, R; Zambon, A | 1 |
| Batra, M; Chaudhuri, A; Dandona, P; Garg, M; Ghanim, H; Hejna, J; Khan, S; Kuhadiya, ND; Makdissi, A; Mehta, A; Torre, B | 1 |
| Broedl, UC; Eilbracht, J; Famulla, S; Kaspers, S; Neubacher, D; Pieber, TR; Soleymanlou, N; Woerle, HJ | 1 |
| Dandona, P; Hansen, L; Henry, RR; Mudaliar, S; Pettus, J; Xu, J | 1 |
| Donnelly, R; Idris, I | 1 |
| Goyal, RK; Lakshmi, S; Padh, H; Rajani, M; Sonawane, RD; Vishwakarma, SL | 1 |
| Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Noda, A; Qun, L; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 1 |
| Grempler, R; Klein, T; Luippold, G; Mark, M | 1 |
| Armstrong, DA; Dobbins, RL; Henry, RR; Hussey, EK; Mavian, AA; Mudaliar, S; Mydlow, PK; Nunez, DJ; O'Connor-Semmes, R; Ye, J | 1 |
| Bazotte, RB; da Costa, MA; de Araújo Funari Ferri, L; de Assis Rocha Neves, F; do Prado, WA; Ferreira, EB | 1 |
| Chang, CL; Chang, SL; Chiang, YM; Chuang, DY; Kuo, HK; Lee, YM; Yang, WC | 1 |
| Cheng, JT; Hsu, FL; Liu, IM; Niu, HS | 1 |
| Barriocanal, LA; Benitez, G; Benitez, S; Jimenez, JT; Jimenez, N; Palacios, M; Rojas, V | 1 |
| Prasad, K | 1 |
21 review(s) available for glucose, (beta-d)-isomer and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Dapagliflozin no longer licensed for type 1 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents; Safety-Based Drug Withdrawals | 2022 |
A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Network Meta-Analysis | 2022 |
Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
Topics: Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Quality-Adjusted Life Years; United Kingdom | 2020 |
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Glucosides; Glycated Hemoglobin; Humans; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin for the treatment of type 1 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2018 |
SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
SGLT inhibitor adjunct therapy in type 1 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemic Agents; International Cooperation; Multicenter Studies as Topic; Observational Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 1 | 2018 |
New Medications for the Treatment of Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
Topics: Animals; Benzhydryl Compounds; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary; Thiophenes | 2015 |
Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2015 |
Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasting; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Humans; Hypoglycemic Agents | 2016 |
Empagliflozin in the treatment of type 2 diabetes: evidence to date.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
31 trial(s) available for glucose, (beta-d)-isomer and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Clamp Technique; Glucosides; Glycemic Control; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Ketosis; Treatment Outcome | 2022 |
Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes.
Topics: Adult; Advanced Oxidation Protein Products; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Glutathione Peroxidase; Humans; Hypoglycemic Agents; Interleukin-6; Metformin; Middle Aged; Superoxide Dismutase | 2022 |
Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan | 2020 |
Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
Topics: Aged; Asian People; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Insulin; Japan; Male; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Trans-Activators; Treatment Outcome | 2020 |
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans | 2020 |
Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.
Topics: Adolescent; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Treatment Outcome; Young Adult | 2021 |
Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Pancreas, Artificial; Pilot Projects; Treatment Outcome | 2021 |
Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Single-Blind Method; Treatment Outcome | 2021 |
Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Benzhydryl Compounds; Child; Cross-Over Studies; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Male; Pilot Projects; Young Adult | 2017 |
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Treatment Outcome; Weight Loss; Young Adult | 2018 |
Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Administration Schedule; Glucosides; Humans; Insulin Resistance; Ketone Bodies; Male; Middle Aged; Pilot Projects; Postprandial Period | 2018 |
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Placebos; Treatment Outcome; Weight Loss | 2018 |
Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glucuronides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
Topics: Adult; Aged; Arteries; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Recovery of Function; Slovenia; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Vasodilation | 2018 |
Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Young Adult | 2019 |
Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Japan; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 1; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Thiophenes | 2019 |
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Female; Glomerular Filtration Rate; Glucose Clamp Technique; Glucosides; Hemodynamics; Humans; Kidney; Male; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2014 |
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 1; Female; Glucosides; Heart Rate; Humans; Male; Prospective Studies; Treatment Outcome; Vascular Stiffness; Young Adult | 2014 |
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2014 |
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2015 |
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Weight Loss; Young Adult | 2015 |
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
Topics: Adult; Austria; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Weight Loss | 2015 |
Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Prognosis; Young Adult | 2016 |
Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome | 2017 |
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
Topics: 3-Hydroxybutyric Acid; Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pilot Projects | 2017 |
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors | 2012 |
Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in Type 1 and Type 2 diabetics.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypotension; Insulin; Male; Middle Aged; Pilot Projects; Sweetening Agents | 2008 |
62 other study(ies) available for glucose, (beta-d)-isomer and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
TLR2- and Dectin 1-associated innate immune response modulates T-cell response to pancreatic β-cell antigen and prevents type 1 diabetes.
Topics: Animals; Antigen-Presenting Cells; Cytokines; Diabetes Mellitus, Type 1; Immunity, Innate; Insulin-Secreting Cells; Lectins, C-Type; Mice; T-Lymphocytes, Regulatory; Toll-Like Receptor 2; Zymosan | 2015 |
Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes.
Topics: Animals; Antigen-Presenting Cells; Cells, Cultured; Coculture Techniques; Crosses, Genetic; Cytokines; Diabetes Mellitus, Type 1; Female; Hyperglycemia; Hyperinsulinism; Immunity, Innate; Lectins, C-Type; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Nerve Tissue Proteins; Prediabetic State; Toll-Like Receptor 2; Zymosan | 2008 |
Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes.
Topics: Adjuvants, Immunologic; Adoptive Transfer; Animals; Cytokines; Diabetes Mellitus, Type 1; Female; Freund's Adjuvant; Interleukin-17; Lipids; Lymph Nodes; Mice; Mice, Inbred NOD; Mice, SCID; Mycobacterium tuberculosis; T-Lymphocytes, Helper-Inducer; Zymosan | 2010 |
Roles for TGF-beta and programmed cell death 1 ligand 1 in regulatory T cell expansion and diabetes suppression by zymosan in nonobese diabetic mice.
Topics: Animals; B7-1 Antigen; B7-H1 Antigen; Cell Differentiation; Cell Line; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Type 1; Dose-Response Relationship, Immunologic; Female; Immunity, Innate; Membrane Glycoproteins; Mice; Mice, Inbred NOD; Mink; Peptides; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Zymosan | 2010 |
Activity of neutrophil β-glucuronidase in diabetic and nondiabetic patients with chronic generalized periodontitis and healthy subjects.
Topics: Adult; Biomarkers; Chronic Periodontitis; Diabetes Mellitus, Type 1; Female; Glucuronidase; Humans; Male; Middle Aged; Neutrophils; Prodigiozan; Spectrometry, Fluorescence; Staphylococcus aureus; Zymosan | 2011 |
Oxygen radical production in human mononuclear blood cells is not suppressed by drugs used in clinical islet transplantation.
Topics: Diabetes Mellitus, Type 1; Humans; Immunosuppressive Agents; Interleukin-1; Islets of Langerhans Transplantation; Leukocytes, Mononuclear; Lipopolysaccharides; Lymphocyte Activation; Methylprednisolone; Niacinamide; Superoxides; Tumor Necrosis Factor-alpha; Zymosan | 1999 |
Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 1; Glucosides; Hypoglycemic Agents; Insulin; Rats; Rodent Diseases | 2021 |
Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Topics: Albuminuria; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Creatinine; Diabetes Mellitus, Type 1; Glomerular Filtration Rate; Glucosides; Hematocrit; Humans; Serum Albumin; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2021 |
Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Drug Therapy, Combination; Glucose; Glucosides; Infusions, Intravenous; Leptin; Male; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients.
Topics: Age Factors; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Retrospective Studies; Weight Loss | 2022 |
Implementation of dapagliflozin as adjunctive therapy in type 1 diabetes: A single centre real-world experience.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Treatment Outcome | 2022 |
SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Heart Failure; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Glucosides; Humans; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2022 |
A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
NICE guidance on dapagliflozin with insulin for type 1 diabetes.
Topics: Benzhydryl Compounds; Consensus; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Protective effects of Salidroside on spermatogenesis in streptozotocin induced type-1 diabetic male mice by inhibiting oxidative stress mediated blood-testis barrier damage.
Topics: Animals; Antioxidants; Blood-Testis Barrier; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Glutathione; Male; Malondialdehyde; Mice; Oxidative Stress; Phenols; Protective Agents; Reactive Oxygen Species; Sperm Count; Spermatogenesis; Spermatozoa; Streptozocin; Superoxide Dismutase; Testis | 2020 |
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin | 2020 |
Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Drug Approval; Europe; Glucosides; Humans; Hypoglycemic Agents | 2020 |
Reduced
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cell Hypoxia; Cell Line; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Fibronectins; Fibrosis; Glucosides; Glycosylation; Humans; Kidney Tubules, Proximal; Male; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2020 |
Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes.
Topics: Animals; Antioxidants; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Male; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m
Topics: Benzhydryl Compounds; Body Mass Index; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents | 2020 |
SGLT2 inhibitors and renal complications in type 1 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Treatment Outcome | 2021 |
Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Insulin; Overweight; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom | 2021 |
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Topics: Adult; Ambulatory Care; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
[Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Female; Glucosides; Glycemic Control; Humans; Hyperglycemia; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2020 |
Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Ketosis; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Ketosis; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
[New Developments in Type 1 Diabetes].
Topics: Benzhydryl Compounds; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemia; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Female; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2021 |
Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Middle Aged; Retrospective Studies; Thiophenes; Treatment Outcome | 2021 |
Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Hypoglycemic Agents; Insulin; Kidney Tubules; Male; Rats, Sprague-Dawley; Renal Elimination; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes; Time Factors; Uric Acid | 2017 |
[Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report].
Topics: Adolescent; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin | 2017 |
Osteoprotective effects of salidroside in ovariectomized mice and diabetic mice.
Topics: Animals; Blood Glucose; Cytoprotection; Diabetes Mellitus, Type 1; Estrogens; Fasting; Femur; Gene Expression Regulation; Glucosides; Kidney; Mice; Mice, Inbred C57BL; Ovariectomy; Phenols; Vitamin D | 2018 |
SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr
Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cholesterol, Dietary; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Heparin; Hyperlipidemias; Lipoproteins; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Phlorhizin; Proteoglycans; Receptors, LDL; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2018 |
Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins | 2018 |
Renal protective effect of Paeoniflorin by inhibition of JAK2/STAT3 signaling pathway in diabetic mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Glucosides; Humans; Janus Kinase 2; Kidney; Macrophages; Male; Mice; Mice, Inbred C57BL; Monoterpenes; Signal Transduction; STAT3 Transcription Factor; Streptozocin | 2018 |
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Computer Simulation; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors; United States; Young Adult | 2019 |
SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Longitudinal Studies; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus.
Topics: Adult; Angiotensins; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Female; Glucosides; Humans; Male; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2019 |
Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus.
Topics: Adolescent; Age Factors; Benzhydryl Compounds; Blood Glucose; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2019 |
A novel approach.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Female; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Kidney; Male; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fatty Liver; Glomerular Filtration Rate; Glucose Intolerance; Glucosides; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Kidney; Liver; Male; Oxidative Stress; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes | 2014 |
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Kidney Glomerulus; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Case-Control Studies; Diabetes Mellitus, Type 1; Female; Glucosides; Glycosuria; Humans; Hyperglycemia; Male; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid; Young Adult | 2015 |
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Pilot Projects; Young Adult | 2015 |
Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Foam Cells; Gene Expression; Glucose Tolerance Test; Glucosides; Hyperglycemia; Hypoglycemic Agents; Macrophages, Peritoneal; Male; Mice; Mice, Knockout; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
European Association for the Study of Diabetes 51st Annual Meeting.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
Topics: Animals; Apoptosis; Area Under Curve; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glucose; Glucose Tolerance Test; Glucosides; Homeostasis; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Organ Size; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 Inhibitors and the Diabetic Kidney.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Kidney Glomerulus; Renin-Angiotensin System; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Amelioration of STZ-induced type 1 diabetic nephropathy by aqueous extract of Enicostemma littorale Blume and swertiamarin in rats.
Topics: Administration, Oral; Animals; Biomarkers; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Drinking; Gentianaceae; Glucosides; Hypertrophy; Hypoglycemic Agents; Iridoid Glucosides; Iridoids; Kidney Glomerulus; Lipids; Male; Plant Extracts; Pyrones; Rats; Rats, Sprague-Dawley; Urea | 2010 |
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastrointestinal Tract; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred ICR; Phlorhizin; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2012 |
Comparative effects of Stevia rebaudiana leaves and stevioside on glycaemia and hepatic gluconeogenesis.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 1; Diterpenes, Kaurane; Gluconeogenesis; Glucose; Glucosides; Hypoglycemic Agents; Liver; Male; Phytotherapy; Plant Extracts; Plant Leaves; Rats; Rats, Wistar; Stevia | 2006 |
Cytopiloyne, a polyacetylenic glucoside, prevents type 1 diabetes in nonobese diabetic mice.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Line; Cell Proliferation; Diabetes Mellitus, Type 1; Female; GATA3 Transcription Factor; Glucosides; Growth Inhibitors; Lymphocyte Activation; Male; Mice; Mice, Inbred NOD; Mice, SCID; Polyynes; T-Box Domain Proteins; Thymidine; Transcription, Genetic; Up-Regulation | 2007 |
Increase of beta-endorphin secretion by syringin, an active principle of Eleutherococcus senticosus, to produce antihyperglycemic action in type 1-like diabetic rats.
Topics: Adrenal Medulla; Adrenalectomy; Animals; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Eleutherococcus; Glucosides; Hyperglycemia; Hypoglycemic Agents; Injections, Intravenous; Male; Mice; Mice, Knockout; Phenylpropionates; Phytotherapy; Rats; Rats, Wistar; Receptors, Opioid, mu; Streptozocin; Tissue Extracts | 2007 |
Oxidative stress as a mechanism of diabetes in diabetic BB prone rats: effect of secoisolariciresinol diglucoside (SDG).
Topics: Animals; Butylene Glycols; Diabetes Mellitus, Type 1; Glucosides; Glycosuria; Humans; Hyperglycemia; Lipid Peroxidation; Malondialdehyde; Oxidative Stress; Pancreas; Rats; Rats, Inbred BB; Reactive Oxygen Species | 2000 |